- Home
- TALK vs SLDB Comparison
TALK vs SLDB Comparison
Compare TALK & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TALK
- SLDB
- Stock Information
- Founded
- TALK 2012
- SLDB 2013
- Country
- TALK United States
- SLDB United States
- Employees
- TALK N/A
- SLDB N/A
- Industry
- TALK Medical/Nursing Services
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TALK Health Care
- SLDB Health Care
- Exchange
- TALK Nasdaq
- SLDB Nasdaq
- Market Cap
- TALK 437.1M
- SLDB 433.0M
- IPO Year
- TALK N/A
- SLDB 2018
- Fundamental
- Price
- TALK $2.49
- SLDB $5.41
- Analyst Decision
- TALK Buy
- SLDB Strong Buy
- Analyst Count
- TALK 6
- SLDB 10
- Target Price
- TALK $4.50
- SLDB $15.00
- AVG Volume (30 Days)
- TALK 1.1M
- SLDB 752.0K
- Earning Date
- TALK 10-28-2025
- SLDB 11-05-2025
- Dividend Yield
- TALK N/A
- SLDB N/A
- EPS Growth
- TALK N/A
- SLDB N/A
- EPS
- TALK 0.02
- SLDB N/A
- Revenue
- TALK $202,611,000.00
- SLDB N/A
- Revenue This Year
- TALK $22.35
- SLDB N/A
- Revenue Next Year
- TALK $20.87
- SLDB N/A
- P/E Ratio
- TALK $146.41
- SLDB N/A
- Revenue Growth
- TALK 17.43
- SLDB N/A
- 52 Week Low
- TALK $1.86
- SLDB $2.41
- 52 Week High
- TALK $4.36
- SLDB $8.10
- Technical
- Relative Strength Index (RSI)
- TALK 50.65
- SLDB 50.71
- Support Level
- TALK N/A
- SLDB N/A
- Resistance Level
- TALK $2.64
- SLDB $5.50
- Average True Range (ATR)
- TALK 0.08
- SLDB 0.28
- MACD
- TALK -0.11
- SLDB -0.20
- Stochastic Oscillator
- TALK 90.22
- SLDB 93.28
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.